Kit Simpson to Ritonavir
This is a "connection" page, showing publications Kit Simpson has written about Ritonavir.
Connection Strength
2.837
-
Lopinavir/ritonavir versus darunavir plus ritonavir for HIV infection: a cost-effectiveness analysis for the United States. Pharmacoeconomics. 2013 May; 31(5):427-44.
Score: 0.414
-
Economic and health-related quality-of-life (HRQoL) comparison of lopinavir/ritonavir (LPV/r) and atazanavir plus ritonavir (ATV+RTV) based regimens for antiretroviral therapy (ART)-na?ve and -experienced United Kingdom patients in 2011. J Med Econ. 2012; 15(4):796-806.
Score: 0.389
-
Economics of switching to second-line antiretroviral therapy with lopinavir/ritonavir in Africa: estimates based on DART trial results and costs for Uganda and Kenya. Value Health. 2011 Dec; 14(8):1048-54.
Score: 0.373
-
Cost-effectiveness analysis of lopinavir/ritonavir and atazanavir+ritonavir regimens in the CASTLE study. Adv Ther. 2009 Feb; 26(2):185-93.
Score: 0.309
-
Comparison of Markov model and discrete-event simulation techniques for HIV. Pharmacoeconomics. 2009; 27(2):159-65.
Score: 0.307
-
Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease. Clin Drug Investig. 2007; 27(1):67-74.
Score: 0.267
-
Cost effectiveness of lopinavir/ritonavir compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the US. Clin Drug Investig. 2007; 27(7):443-52.
Score: 0.267
-
Cost effectiveness of lopinavir/ritonavir tablets compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the UK, France, Italy and Spain. Clin Drug Investig. 2007; 27(12):807-17.
Score: 0.267
-
Broadening the perspective when assessing evidence on boosted protease inhibitor-based regimens for initial antiretroviral therapy. Adv Ther. 2010 Nov; 27(11):763-73.
Score: 0.087
-
Cost-effectiveness of tipranavir in treatment-experienced HIV patients in the United States. HIV Clin Trials. 2008 Jul-Aug; 9(4):225-37.
Score: 0.074
-
Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection. HIV Clin Trials. 2004 Sep-Oct; 5(5):294-304.
Score: 0.057
-
Cost-minimization comparison of darunavir plus ritonavir and lopinavir/ritonavir in HIV-1 infected treatment-na?ve women of childbearing age. J Med Econ. 2014 Apr; 17(4):250-8.
Score: 0.027